Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 11, Issue 4, Pages 288-293Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2011.04.011
Keywords
-
Categories
Funding
- Italian Association for Cancer Research (AIRC)
Ask authors/readers for more resources
Constitutive activation of NF-kappa B occurs in a significant percentage of human cancers. Genetic abnormalities of tumors often enhance normal NF-kappa B signaling. Chronic inflammation is also associated with constitutive NF-kappa B activation and increases the risk of cancer. Aberrant NF-kappa B activation favors cellular transformation, sustains cancer survival, and contributes to tumor invasion. Strategies to inhibit NF-kappa B represent a promising therapeutic option against cancer. In the last decade, several studies point to the large immunophilin FKBP51 as an important element for the control of NF-kappa B activation in human neoplasia. This article is an overview of the causes of aberrant NF-kappa B regulation in cancer and highlights recent papers that implicate FKBP51 in such deregulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available